• Recruiting

NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT

Updated: Sep 2


NCT05130827: Phase 2: Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Plinabulin beyond spring pharma

NCT05130827: Phase 2: Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)


This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrastim after undergoing an autologous hematopoietic stem cell transplant (AHCT).


Sponsor

Memorial Sloan Kettering Cancer Center


Collaborator

BeyondSpring Pharmaceuticals Inc.

 

ClinicalTrials.gov Identifier: NCT05130827


Official Title: Pilot Trial of Plinabulin and Pegfilgrastim to Reduce the Duration of Absolute Neutropenia After Autologous Hematopoietic Cell Transplantation for Patients With Multiple Myeloma

First Posted : November 23, 2021


Click here for details on ClinicalTrials.gov

 

Plinabulin

Plinabulin (Code C62444)

NPI-2358

Plinabulin

PLINABULIN


Pegfilgrastim

Pegfilgrastim (Code C1854)

Filgrastim SD-01

filgrastim-SD/01

Fulphila

HSP-130

Jinyouli

Neulasta

Neulastim

Nyvepria

PEG-filgrastim

Pegcyte

Pegfilgrastim

pegfilgrastim

PEGFILGRASTIM

Pegfilgrastim Biosimilar HSP-130

Pegfilgrastim Biosimilar Nyvepria

Pegfilgrastim Biosimilar Pegcyte

Pegfilgrastim Biosimilar PF-06881894

Pegfilgrastim Biosimilar Udenyca

Pegfilgrastim Biosimilar Ziextenzo

pegfilgrastim-apgf

pegfilgrastim-bmez

pegfilgrastim-cbqv

Pegfilgrastim-jmdb

PF-06881894

SD-01

SD-01 sustained duration G-CSF

Udenyca

Ziextenzo


US brand name:

Fulphila

Neulasta

Nyvepria

Udenyca

Ziextenzo


Foreign brand name:

Jinyouli

Neulastim

Pegcyte

 

Drug: Plinabulin

 

Location

United States, New York

Posts Archive